Hemocit-P Tablet is a combination pharmaceutical formulation containing Citicoline 500 mg and Piracetam 800 mg, indicated for the management of cognitive disorders and neurological conditions associated with impaired brain function. Citicoline, a neuroprotective agent, serves as a precursor in the biosynthesis of phosphatidylcholine, a key component of neuronal membranes, thereby enhancing membrane repair and promoting neuroplasticity. It also facilitates the restoration of neurotransmitter levels, particularly acetylcholine, contributing to improved cognitive processes such as memory and attention. Piracetam, a nootropic agent, modulates neuronal excitability and enhances cerebral blood flow and oxygen utilization, which supports cognitive enhancement and neuroprotection. The synergistic action of Citicoline and Piracetam in Hemocit-P Tablet is beneficial in treating conditions such as stroke recovery, vascular dementia, cognitive impairment due to aging, and other neurodegenerative disorders. This combination improves mental alertness, memory retention, and learning capacity while also aiding in the rehabilitation of neurological deficits. Hemocit-P should be used under medical supervision, with dosage tailored to individual patient needs. Common adverse effects are generally mild and may include gastrointestinal discomfort, headache, or nervousness. Caution is advised in patients with hypersensitivity to either component or those with severe renal impairment.